Do you have the same question? Follow this Question
Mar 06, 2026 - 11:22 AM
We’ve provided several answers to questions related to Lagevrio (Molnupiravir) , see some other helpful Q&A related to this product.
Question: Is this medication available for pediatric patients?
Answer: No, this medication is not authorized for use in patients younger than 18 years old because it may affect the growth of bone and cartilage. This restriction helps ensure patient safety in the pediatric population.
Question: What is the PubChem CID for this medication?
Answer: The PubChem CID is 145996610. PubChem is a chemical database maintained by the National Institutes of Health, helpful for those researching drug properties.
Question: What is the legal status of this medication?
Answer: It is available under emergency use authorization in the US and conditional approval in the UK. These statuses mean the medication is available for use during public health emergencies, providing access when needed most.
Question: What is the bioavailability of this medication?
Answer: The bioavailability is about 100% as a prodrug, meaning almost all of the drug is available in the body after oral administration. High bioavailability ensures the medication works efficiently.
Question: What is the recommended dosage for adults?
Answer: The recommended dosage is 800 mg (which is four 200 mg capsules) taken by mouth every 12 hours for 5 days. Following the correct dosing schedule maximizes treatment effectiveness and minimizes risks.
